Hormonal
Semaglutide subcutaneous (SQ) at 2.4 mg produces the greatest weight loss among GLP-1 analogs, significantly outperforming other agents including lower-dose semaglutide and liraglutide.
If you are seeking the most effective pharmacological weight loss treatment available in this class, semaglutide administered subcutaneously at 2.4 mg is the superior choice. It produces significantly greater weight loss than other GLP-1 analogs like liraglutide or lower-dose semaglutide. Be aware that this higher efficacy comes with a higher risk of gastrointestinal side effects, though it is not the highest risk among all GLP-1 agents.
Network meta-analysis showed that semaglutide SQ 2.4mg was associated with excess weight loss compared to all other active agents... SUCRA-based treatment ranking suggested that semaglutide SQ 2.4mg (SUCRA, 100) was most likely to result in the highest excess weight loss, followed by semaglutide <2.4mg (SUCRA, 86.1), liraglutide >1.8mg (SUCRA, 82.8)
Why this rating
Based on 64 RCTs and 27,018 patients using network meta-analysis with high certainty of evidence for head-to-head comparisons.
Source
Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis
Kia Vosoughi et al. · EClinicalMedicine · 2021
DOI 10.1016/j.eclinm.2021.101213
More from this paper
- Semaglutide oral is effective for weight loss compared to placebo, but is less effective than subcutaneous semaglutide formulations.Limited
- All GLP-1 analogs and agonists are associated with a higher risk of discontinuation due to adverse events compared to placebo, with taspoglutide and high-dose liraglutide having the highest risk.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →